Desolvation process and surface characteristics of HSA-nanoparticles

Weber, Carolin; Kreuter, Jörg; Langer, Klaus

doi:10.1016/s0378-5173(99)00420-2

Cited by 150 publications

(103 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study is based on our earlier work (Weber et al, 2000b) describing a desolvation method for HSA particle preparation and their characterization with respect to size, zetapotential and the number of available amino groups on their surface. In the earlier study, the amount of the desolvating agent ethanol in the desolvation process was found to control particle size, but the variability in size at a given ethanol amount was high.…”

Section: Resultsmentioning

confidence: 99%

“…HSA nanoparticles were prepared by a desolvation technique as described previously (Marty et al, 1978;Weber et al, 2000b). In principle, between 50 and 200 mg HSA in 2.0 ml of purified water or 10 mM NaCl solution, respectively, both titrated to pH 7-10, were transformed into nanoparticles by the continuous addition of 8.0 ml of the desolvating agent ethanol under stirring (500 rpm) at room temperature.…”

Section: Preparation Of Hsa Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Optimization of the preparation process for human serum albumin (HSA) nanoparticles

Langer¹,

Balthasar²,

Vogel³

et al. 2003

International Journal of Pharmaceutics

650

491

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Preparation Of Hsa Nanoparticlesmentioning

confidence: 99%

Optimization of the preparation process for human serum albumin (HSA) nanoparticles

Langer¹,

Balthasar²,

Vogel³

et al. 2003

International Journal of Pharmaceutics

650

491

View full text Add to dashboard Cite

“…Various studies have been reported on the effect of different process parameters such as pH (4), temperature (12), amount of glutaraldehyde (12), stirring rate (13), type of buffer, desolvating agent (4,13), and protein concentration (4,13) on the size and size distribution of HSA NPs.…”

mentioning

confidence: 99%

The Effects of Organic Solvents on the Physicochemical Properties of Human Serum Albumin Nanoparticles

et al. 2016

View full text Add to dashboard Cite

“…34 In the literature, three methods exist for the preparation of human serum albumin-based nanoparticles based on emulsion formation, desolvation, or coacervation processes. [35][36][37] In order to stabilize the resulting nanoparticles, glutaraldehyde can be used as the crosslinking agent. 37,38 However, to date, the application of nanoparticles towards the encapsulation of growth factors is lacking.…”

Section: Introductionmentioning

confidence: 99%

“…[35][36][37] In order to stabilize the resulting nanoparticles, glutaraldehyde can be used as the crosslinking agent. 37,38 However, to date, the application of nanoparticles towards the encapsulation of growth factors is lacking. The objective of this study was to investigate the feasibility of entrapping the growth factors, human VEGF and human angiopoietin-1, in nanoparticles crosslinked with glutaraldehyde to enable potential application in therapeutic angiogenesis.…”

Section: Introductionmentioning

confidence: 99%

Mitotic and antiapoptotic effects of nanoparticles coencapsulating human VEGF and human angiopoietin-1 on vascular endothelial cells

Khan

Paul²,

Abbasi³

et al. 2011

IJN

View full text Add to dashboard Cite

Background: Research towards the application of nanoparticles as carrier vehicles for the delivery of therapeutic agents is increasingly gaining importance. The angiogenic growth factors, human vascular endothelial growth factor (VEGF) and human angiopoietin-1 are known to prevent vascular endothelial cell apoptosis and in fact to stimulate human vascular endothelial cell (HUVEC) proliferation. This paper aims to study the combined effect of these bioactive proteins coencapsulated in human serum albumin nanoparticles on HUVECs and to evaluate the potential application of this delivery system towards therapeutic angiogenesis. Methods and results: The angiogenic proteins, human VEGF and human angiopoietin-1, were coencapsulated in albumin nanoparticles for better controlled delivery of the proteins. The application of a nanoparticle system enabled efficient and extended-release kinetics of the proteins. The size of the nanoparticles crosslinked with glutaraldehyde was 101.0 ± 0.9 nm and the zeta potential was found to be −18 ± 2.9 mV. An optimal concentration of glutaraldehyde for the nanoparticle coating process was determined, and this provided stable and less toxic nanoparticles as protein carriers. The results of the study indicate that nanoparticles crosslinked with glutaraldehyde produced nanoparticles with tolerable toxicity which provided efficient and controlled release of the coencapsulated proteins. The nanoparticles were incubated for two weeks to determine the release profiles of the proteins. At the end of the two-week incubation period, it was observed that 49% ± 1.3% of human angiopoietin-1 and 59% ± 2.1% of human VEGF had been released from the nanoparticles. The proliferation and percent apoptosis of the HUVECs in response to released proteins was observed. Conclusion: The results indicate that the released proteins were biologically active and the combined application of both the proteins demonstrated a significant highly proliferative and antiapoptotic effect on HUVECs as compared with the effect demonstrated by the individual proteins released. These studies could serve as a basis to encourage further research into the potential in vivo application of these protein-loaded nanoparticles in the field of therapeutic angiogenesis.

show abstract

Desolvation process and surface characteristics of HSA-nanoparticles

Cited by 150 publications

References 6 publications

Optimization of the preparation process for human serum albumin (HSA) nanoparticles

Optimization of the preparation process for human serum albumin (HSA) nanoparticles

The Effects of Organic Solvents on the Physicochemical Properties of Human Serum Albumin Nanoparticles

Mitotic and antiapoptotic effects of nanoparticles coencapsulating human VEGF and human angiopoietin-1 on vascular endothelial cells

Contact Info

Product

Resources

About